Management of paroxysmal nocturnal hemoglobinuria (PNH)

PNH is a chronic hemolytic disorder due to an intrinsic red cell abnormality. There is no evidence that either prolonged administration of corticosteroids or chemotherapy are beneficial in PNH. On the other hand, patients can live with PNH for many years with supportive management. At the moment com...

Descripción completa

Detalles Bibliográficos
Autor principal: Luzzatto, Lucio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756976/
https://www.ncbi.nlm.nih.gov/pubmed/36378554
http://dx.doi.org/10.1002/jcla.24770
_version_ 1784851731756089344
author Luzzatto, Lucio
author_facet Luzzatto, Lucio
author_sort Luzzatto, Lucio
collection PubMed
description PNH is a chronic hemolytic disorder due to an intrinsic red cell abnormality. There is no evidence that either prolonged administration of corticosteroids or chemotherapy are beneficial in PNH. On the other hand, patients can live with PNH for many years with supportive management. At the moment complement inhibitor therapy is indicated in most cases; and it is highly desirable that the current financial barriers to this therapy be overcome.
format Online
Article
Text
id pubmed-9756976
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97569762022-12-20 Management of paroxysmal nocturnal hemoglobinuria (PNH) Luzzatto, Lucio J Clin Lab Anal Commentary PNH is a chronic hemolytic disorder due to an intrinsic red cell abnormality. There is no evidence that either prolonged administration of corticosteroids or chemotherapy are beneficial in PNH. On the other hand, patients can live with PNH for many years with supportive management. At the moment complement inhibitor therapy is indicated in most cases; and it is highly desirable that the current financial barriers to this therapy be overcome. John Wiley and Sons Inc. 2022-11-15 /pmc/articles/PMC9756976/ /pubmed/36378554 http://dx.doi.org/10.1002/jcla.24770 Text en © 2022 The Author. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Commentary
Luzzatto, Lucio
Management of paroxysmal nocturnal hemoglobinuria (PNH)
title Management of paroxysmal nocturnal hemoglobinuria (PNH)
title_full Management of paroxysmal nocturnal hemoglobinuria (PNH)
title_fullStr Management of paroxysmal nocturnal hemoglobinuria (PNH)
title_full_unstemmed Management of paroxysmal nocturnal hemoglobinuria (PNH)
title_short Management of paroxysmal nocturnal hemoglobinuria (PNH)
title_sort management of paroxysmal nocturnal hemoglobinuria (pnh)
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756976/
https://www.ncbi.nlm.nih.gov/pubmed/36378554
http://dx.doi.org/10.1002/jcla.24770
work_keys_str_mv AT luzzattolucio managementofparoxysmalnocturnalhemoglobinuriapnh

Ejemplares similares